DSDorothy K. Sit

Dorothy K. Sit

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dorothy K. Sit has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Amy Yang

    Department of Preventive Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA

    2 shared publications
  • Crystal T. Clark

    Department of Psychiatry and Behavioral Sciences, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA; Department of Obstetrics and Gynecology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA

    2 shared publications
  • Emily Pinheiro

    Department of Psychiatry and Behavioral Sciences, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA

    2 shared publications
  • Jody D. Ciolino

    Department of Preventive Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA

    2 shared publications
  • Katherine L. Wisner

    Developing Brain Institute, Children’s National Hospital, Washington, DC 20010, USA

    2 shared publications
  • Addie Li

    Asher Center for the Study and Treatment of Depressive Disorders, Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, USA

    1 shared publication

Latest Publications

  • Open Access

    Light therapy for bipolar disorders: Clinical recommendations from the international society for bipolar disorders (ISBD) Chronobiology and Chronotherapy Task Force

    by Pierre A. Geoffroy, Laura Palagini, Tone E. G. Henriksen, Patrice Bourgin, Corrado Garbazza, Claude Gronfier, Yuichi Esaki, Diego C. Fernandez, Raymond W. Lam, Heon-Jeong Lee, et al.

    The International Society for Bipolar Disorders (ISBD) Chronobiology and Chronotherapy Task Force conducted a comprehensive review to deliver concise evidence-based recommendations on the use of bright light therapy (BLT) for bipolar disorder (BD). Adjunctive BLT is likely an efficacious acute treatment for bipolar depression as implicated by higher quality evidence. The position of maintenance BLT for relapse prevention awaits further investigation. Protocols of effective BLT in BD are similar to parameters indicated for treatment of seasonal and non-seasonal major depressive disorder. Anti-manic prophylaxis (especially for BD-I) and clinical monitoring are recommended with initiation of and ongoing light treatment. Administer BLT daily, preferably in the morning or at mid-day. If mornings are prohibitive, then mid-day exposure, implemented to avoid excessively early wake times, is an acceptable alternative. Informed by the literature, target 30 min/day of BLT exposure. Patients wary of emergent hypomania or partial responders, can initiate 15 min/day and increase by 15 min each week to full response (or 30-60 min/day by the fourth week). Consider patient centred outcome assessments to evaluate mood response, safety and side effects. Clinical improvement is typically observed within 1-2 weeks, with response/remission expected by 4-6 weeks. Integration of BLT with other chronotherapeutic strategies may enhance long-term efficacy.


  • Depression in Persons With Epilepsy

    by Kathryn Do Abell, Dorothy K. Sit, Katherine L. Wisner

    Background Major depressive disorder is highly prevalent among persons with epilepsy (PWEs). Between 30% and 50% of PWEs suffer from depression. Many factors contribute to this prevalence, including the psychosocial impact of the diagnosis, restrictions on driving and certain types of work, and adverse effects associated with antiseizure medications. Without proper treatment, depressed PWEs have increased risks for suicide, strained relationships, lowered seizure control, and impairment in functioning. Our objective was to use the existing literature and insights from our experience in treating depression and anxiety in PWEs within an academic mood disorders center. We aimed to provide practical guidance for health care professionals who treat depression in this population. TABLE 1 - Twelve Cases of PWEs With Depression: Clinical Characteristics and Depression Treatments Case Number Age, y Type of Epilepsy ASMs Psychiatric Diagnosis Comorbidity Psychiatric Meds Therapy Bright Light Therapy 1 38 Partial epilepsy (medical condition) Lamotrigine MDD, anxiety ADHD Sertraline, trazodone, methylphenidate Couples therapy, individual therapy 2 35 Focal epilepsy Oxcarbazepine, valproic acid MDD recurrent, GAD Venlafaxine, clonazepam Couples therapy, individual therapy Yes 3 41 Generalized epilepsy Zonisamide, clobazam, levetiracetam MDD recurrent, Mirtazapine, buspirone Individual therapy 4 30 Generalized epilepsy Lamotrigine MDD PMDD Escitalopram, trazodone Individual therapy Yes 5 42 Focal epilepsy (cancer) Clobazam, lamotrigine GAD, OCD ADHD Escitalopram, modafinil Individual therapy 6 35 Focal epilepsy Lamotrigine, oxcarbazepine MDD recurrent, Sertraline Individual therapy Yes 7 43 Simple partial epilepsy (s/p surgical procedure) Brivaracetam, lamotrigine MDD, GAD PTSD, alcohol use Venlafaxine Individual therapy 8 54 Focal epilepsy, as well as PNES Lamotrigine, clonazepam, phenytoin MDD, recurrent Trauma history Escitalopram, aripiprazole None 9 28 Paroxysmal events (epilepsy vs PNES) Lacosamine, brivaracetam, clonazepam MDD, recurrent Trauma history Duloxetine None Yes 10 57 Generalized epilepsy Zonisamide, lamotrigine, clobazepam, MDD vs PDD Fluoxetine None Yes 11 39 Focal epilepsy Lamotrigine MDD PTSD, alcohol, cannabis Duloxetine, quetiapine Therapy 12 32 Generalized epilepsy Valproic acid MDD recurrent Sertraline, trazodone None ADHD indicates attention deficit hyperactivity disorder; GAD, generalized anxiety disorder; MDD, major depressive disorder; OCD, obsessive-compulsive disorder; PMDD, premenstrual dysphoric disorder; PNES, paroxysmal non-epileptic seizures; PTSD, posttraumatic stress disorder. Methods Persons with epilepsy and depression were identified by their treating psychiatrists. Their electronic health records were reviewed and compiled for this report, with a total of 12 included in this review. Records were reviewed regarding antiseizure medications, psychotropic medications, light therapy, psychotherapy, other interventions, and treatment response. Results Based on our review of literature, as well as review of cases of individuals with epilepsy and comorbid psychiatric conditions, we recommend a step-wise evidence-based approach of optimizing psychiatric medication doses, augmenting with additional medication and/or implementing nonpharmacological interventions such as light therapy and psychotherapy. Conclusions In PWEs, improvement in depression, other psychiatric symptoms, and function are the goals of drug and nondrug interventions. Depression care has the potential to significantly improve the quality of life of PWEs and reduce both morbidity and mortality.


  • Light Therapy for Adolescent Depression: A Scoping Review

    by Rachel Ballard, John Parkhurst, Kelsey Julian, Lauren N. Pasetes, Andrea Fawcett, Addie Li, Namni Goel, Dorothy K. Sit

    Purpose Depressive disorders in adolescents are a major health concern associated with developmental, social, and educational impairment. Bright Light Therapy (BLT) is a feasible and effective treatment for depressive disorders in adults, but few controlled trials have been conducted with children or adolescents. This scoping review focuses on the current state of knowledge for BLT in the treatment of adolescent depression. We reviewed the literature for novel data and methodologic approaches using BLT and pediatric and young adult populations. Recent Findings BLT is a tolerable treatment with few side effects. However, there is a marked lack of well-powered studies to support BLT as a treatment for depressive disorders in adolescent populations. Summary Given evidence of tolerability and positive treatment effect on depression in the adult literature, research is needed to establish the efficacy, feasibility, and acceptability of BLT in adolescents.


  • Validity of the WHIPLASHED as a tool to identify bipolar disorder in women

    by Dana R. Mahmoud, Amy Yang, Jody D. Ciolino, Sheehan D. Fisher, Dorothy Sit, Emily Pinheiro, Tricia Pendergrast, Kelly O'SHea, Katherine L. Wisner, Crystal T. Clark


  • Bipolar disorder and psychotropic medication: Impact on pregnancy and neonatal outcomes

    by Katherine L. Wisner, Dorothy Sit, Kelly O'Shea, Debra L. Bogen, Crystal T. Clark, Emily Pinheiro, Amy Yang, Jody D. Ciolino